# AL-273

Source: https://onco.cc/drugs/al-273/  
OnCo record `al-273` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AL-273 is an experimental small molecule from Alaw Therapeutics, at a stage the company does not state for EGFR-driven tumours.

## Summary

AL-273 is a small molecule from Alaw Therapeutics. A next-generation pan-mutant EGFR inhibitor designed to cover a broad range of clinically relevant EGFR mutations, including resistance-associated variants. The company does not state its stage; it is aimed at EGFR-driven tumours. No clinical trial naming it is registered on ClinicalTrials.gov. Stage not stated on the pipeline page; no registered trial found, and the May 2026 release names only AL-605 as clinical. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Last checked: 2026-11-03
- Tags: pipeline
- Code: AL-273
- Modality: Small molecule
- Mechanism: A next-generation pan-mutant EGFR inhibitor designed to cover a broad range of clinically relevant EGFR mutations, including resistance-associated variants.

## Sources

- Alaw Therapeutics: alawtx.com: https://www.alawtx.com/pipeline

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- companies: [Alaw Therapeutics](https://onco.cc/companies/alaw-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/al-273.json